These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16027100)

  • 1. Translational research in myelodysplastic syndromes.
    Raza A; Qawi H; Mehdi M; Mumtaz M; Galili N
    Rev Clin Exp Hematol; 2004 Dec; 8(2):E2. PubMed ID: 16027100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New agents in myelodysplastic syndromes.
    Jabbour EJ; Giles FJ
    Curr Hematol Rep; 2005 May; 4(3):191-9. PubMed ID: 15865871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD
    J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in myelodysplastic syndromes.
    Shadduck RK; Latsko JM; Rossetti JM; Haq B; Abdulhaq H
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):137-43. PubMed ID: 17379099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of angiogenesis in the biology and therapy of myelodysplastic syndromes.
    Aguayo A
    Curr Hematol Rep; 2004 May; 3(3):184-91. PubMed ID: 15087066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapies in myelodysplastic syndrome.
    Melchert M; List A
    Semin Hematol; 2008 Jan; 45(1):31-8. PubMed ID: 18179967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supportive care, growth factors, and new therapies in myelodysplastic syndromes.
    Hellström-Lindberg E; Malcovati L
    Blood Rev; 2008 Mar; 22(2):75-91. PubMed ID: 18068281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.
    Komrokji RS; List AF
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):377-88. PubMed ID: 20359632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulatory drugs in the treatment of myelodysplastic syndromes.
    Ortega J; List A
    Curr Opin Oncol; 2007 Nov; 19(6):656-9. PubMed ID: 17906467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel agents for the management of myelodysplastic syndromes.
    Meletis J; Viniou N; Terpos E
    Med Sci Monit; 2006 Sep; 12(9):RA194-206. PubMed ID: 16940944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.
    Melchert M; Kale V; List A
    Curr Opin Hematol; 2007 Mar; 14(2):123-9. PubMed ID: 17255789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS).
    List AF
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S31-5. PubMed ID: 16085015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives.
    Musto P
    Leuk Res; 2004 Apr; 28(4):325-32. PubMed ID: 15109529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of angiogenesis in patients with myelodysplastic syndrome.
    Estey EH
    Best Pract Res Clin Haematol; 2004 Dec; 17(4):623-39. PubMed ID: 15494299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses.
    Giagounidis AA; Haase S; Heinsch M; Göhring G; Schlegelberger B; Aul C
    Ann Hematol; 2007 Feb; 86(2):133-7. PubMed ID: 17111142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of lenalidomide in the management of myelodysplasia with del 5q.
    Kelaidi C; Eclache V; Fenaux P
    Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New approaches to the treatment of myelodysplasia.
    List AF
    Oncologist; 2002; 7 Suppl 1():39-49. PubMed ID: 11961208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New therapeutics for myelodysplastic syndromes.
    List AF
    Leuk Res; 2012 Dec; 36(12):1470-4. PubMed ID: 22959510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.
    Cilloni D; Messa E; Messa F; Carturan S; Defilippi I; Arruga F; Rosso V; Catalano R; Bracco E; Nicoli P; Saglio G
    Ann N Y Acad Sci; 2006 Nov; 1089():411-23. PubMed ID: 17261784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
    Loiseau C; Ali A; Itzykson R
    Exp Hematol; 2015 Aug; 43(8):661-72. PubMed ID: 26123365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.